US drug major Bristol-Myers Squibb's first-quarter 2009 profit fell 3.5% year-on-year to $638.0 million, despite a 3% rise in revenue to $5.02 billion, due to higher taxes and a heavy litigation charge.
The company made a one-off payment of $104.0 million, largely to settle a shareholder law suit, while restructuring charges more than doubled to $27.0 million.
Despite a difficult market environment, in February, B-MS made $800.0 million by selling a 17% stake in its Mead Johnson Nutrition business. The firm retains 83% owner-ship, to help diversify risk while enhancing management focus on biopharmaceuticals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze